BCG site inflammation: A useful diagnostic sign in incomplete Kawasaki disease

Journal of Paediatrics and Child Health

Volumn 44, Issue 9, 2008, Pages 525-526

  Chalmers, Debbie ^a   Corban, Jenny G ^a   Moore, Philip P C ^a  

^a HAWKE S BAY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BCG VACCINE; C REACTIVE PROTEIN; COTRIMOXAZOLE; HEMOGLOBIN;

ARTERY DIAMETER; CLINICAL FEATURE; DISEASE DURATION; FEBRILE BONE MARROW APLASIA; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE INFLAMMATION; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; LOW DRUG DOSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OTITIS MEDIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; VIRUS INFECTION;

BCG VACCINE; FEMALE; HUMANS; INFANT; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 50049112947     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2008.01364.x     Document Type: Letter

References (8)

1. Newberger J, Takahashi M, Gerber M et al. Diagnosis, treatment and long-term management of Kawasaki disease. Circulation 2004 110 : 2747 71.
2. Heaton P, Wilson N, Nicholson R, Doran J, Parsons A, Aiken G. Kawasaki disease in New Zealand. J. Paediatr. Child Health 2006 42 : 184 90.
3. Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience. J. Pediatr. Child Health 2004 40 : 524 9.
4. Antony D, Jessy P. Involvement of BCG scar in Kawasaki disease (letter). Indian Pediatr. 2005 42 : 83 4.
5. Weinstein M. Inflammation at a previous inoculation site: an unusual presentation of Kawasaki disease. CMAJ 2006 174 : 459 60.
6. Sinha R, Balakumar T. BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease. Arch. Dis. Child 2005 90 : 891.
7. Sireci G, Dieli F, Salerno A. T cells recognize an immunodommunant epitope of heat shock proten 65 in Kawasaki disease. Mol. Med. 2000 6 : 581 90.
8. Hsu Y, Wang Y, Hsu W, Lee Y. Kawasaki disease characterized by erythema and induration at the bacillus Calmette-Guerin and purified protein derivative inoculation sites. Pediatr. Infect Dis. J. 1987 6 : 576 8.